March 28 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB RECEIVES POSITIVE CHMP OPINION FOR THE SUBCUTANEOUS FORMULATION OF OPDIVO® (NIVOLUMAB) ACROSS MULTIPLE SOLID TUMOR INDICATIONS
BRISTOL-MYERS SQUIBB CO - EU DECISION ON OPDIVO MARKETING AUTHORIZATION EXPECTED BY JUNE 2, 2025
Source text: ID:nBwbS4b4Ja
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.